Table 3

Biomarker concentrations and routine CSF parameters for patients with diagnoses Parkinson syndrome, polyneuropathy and facial palsy

DiagnosisnNfL (pg/mL)pNfH (pg/mL)Tau (pg/mL)pTau (pg/mL)Qalbtotal protein (µg/mL)
Parkinson syndrome
 Idiopathic Parkinson disease141103
439–2859
510
109–1110
303
170–627
37
24–73
6.4
4.2–8.9
468
283–688
 Parkinson’s disease dementia72077
976–3157
382
79–769
222
161–559
43
28–112
5.9
3.8–12.0
446
257–807
 Multiple system atrophy31082
1078–2673
625
403–856
201
174–340
35
33–54
6.0
2.7–9.3
451
104–798
 Progressive supranuclear palsy23329
1816–4841
916
601–1228
248
171–324
49
44–54
7.3
6.9–7.6
536
514–558
Polyneuropathy
 Axonopathy16991
431–18 970
475
86–8240
271
106–745
42
18–92
6.4
2.7–12.8
480
225–956
 Demyelinating4866
595–983
415
134–635
161
110–394
33
31–52
6.1
2.8–8.8
443
233–754
 Both (axonal and demyelinating)91322
377–1835
313
168–687
225
52–481
38
25–62
6.8
4.4–11.6
574
304–918
 Guillain–Barré syndrome12940278202329.3796
 Others127714524334
 Polymyalgia rheumatica*124 33019324463117.81020
 Spondylodiscitis*123 37037 6203192619.11260
Facial palsy
 Idiopathic24556.5
100–2676
236
62–919
258
77–527
38.5
23–72
5.8
2.8–16.4
469
226–1140
 Herpes zoster2796
573–1019
382
282–481
313
157–469
37
36–37
4.0
3.8–4.0
332
304–359
 Ischaemic2401
395–406
154
73–235
182
162–201
39
34–43
5
3.2–6.5
401
294–419
 Miller-Fisher syndrome18463461472112.1811
 Neurinoma1683375189328.1661
  • Given are the median values and ranges.

  • *Patients initially seen under the differential diagnosis polyneuropathy.

  • CSF, cerebrospinal fluid; NfL, neurofilament light chain; pNfH, phosphorylated heavy chain; pTau, phospho-tau protein; Qalb, CSF/serum albumin ratio; Tau, tau protein.